ADVERTISEMENT
Preferences for Second-Line PARP Inhibitor Maintenance in Ovarian Cancer
Findings from a recent study analyzing patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer suggest that the progression-free survival (PFS) gains observed in selected studies of poly (ADP-ribose) polymerase (PARP) inhibitors in BRCA-mutated disease are worth the toxicity risk (Future Oncol. 2021. doi:10.2217/fon-2021-0567).
The study, conducted by Rebecca Stone, MD, Johns Hopkins School of Medicine, Baltimore, MD, and colleagues, aimed to understand preferences of patients and oncologists in the United States regarding PARP inhibitors as second-line maintenance for epithelial ovarian cancer. Preferences of treatment attributes were analyzed through a discrete choice experiment.
Among participants, the most valued attributes were risk of grade 3/4 adverse events (AEs) and PFS, observed in 204 patients and 151 oncologists, respectively. PFS would need to increase by 27.9 months for patients and 6.3 months for oncologists in order to accept a 37% increased risk of grade 3/4 AEs. Authors observed that for patients, the least valued attributes were dosing form/frequency, while for oncologists, it was grade 3/4 anemia risk.
“Patients' and oncologists' willingness to make benefit-risk trade-offs in the 2LM setting suggests that the PFS gains observed in selected studies of [PARP] inhibitors in BRCA-mutated disease are worth the toxicity risk,” concluded Dr Stone and colleagues.
